drugset / Trial / NCT05835011
A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of the study is to evaluate the preliminary safety and efficacy of oral decitabine/cedazuridine in combination with magrolimab.
Timeline
- Start
- 2023-06-27
- Primary completion
- 2023-08-21
- Completion
- 2023-08-21
Outcome
Outcome not reported
Stopped: “Termination due to discontinuation of magrolimab development in MDS.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cedazuridine | Small molecule | 100 mg | Oral |
| Subject | Decitabine | Small molecule | 35 mg | Oral |
| Subject | Magrolimab | Monoclonal antibody | 30 mg/kg | Intravenous |